Will the NHS be ‘for sale’ after Brexit?
May refuses to rule out opening up the NHS to US drug companies as part of post-Brexit deal
Theresa May has stoked fears the NHS could be opened up for exploitation by US drug firms as part of a post-Brexit trade deal, refusing to say the health service would be excluded from future talks.
Responding to a question in the Commons from Liberal Democrats leader Vince Cable, the Prime Minister said it was too early to judge what “requirements” the US would have for post-Brexit trade discussions.
“The Prime Minister knows that one of the key objectives of American trade negotiators in any future deal after Brexit is to secure access for American companies to business in the NHS,” Cable said.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
“Can she give an absolute guarantee that in those negotiations the NHS will be excluded from their scope, and can she confirm that in her conversations with President Trump she’s made it absolutely clear to him that the NHS is not for sale?”
May’s critics warned that the US would use any future deal to demand the health service was opened up to private firms from across the Atlantic.
Her answer was seized on by Labour MP Peter Kyle, a supporter of the pro-EU Open Britain campaign, who said: “Theresa May just gave Donald Trump the green light to get his hands on our National Health Service.”
Labour’s shadow health secretary, Jon Ashworth, has previously warned a trade deal could lead to “stealth privatisation” of the NHS.
The proportion of health service contracts being won by non-NHS firms ballooned to almost 70% last year, says The Independent. “Critics say this rising ‘privatisation’ has opened the door to US health firms, who already view the NHS as a goldmine,” adds the paper.
Turning the question on its head, The Economist asks whether American companies actually want to invest in the NHS. Might they instead stick to the far more profitable private healthcare system in Britain, the magazine asks.
“Government spending on health as a share of GDP is lower in Britain than in most of western Europe and the gap is forecast to increase. Many NHS trusts are in deficit. And dealing with the NHS can be a messy and frustrating business, far removed from the cash-rich American health-care machine,” the magazine argues.
Under a recent EU directive which means health commissioners must tell the open market when any NHS contract is being tendered, there’s even an argument that “remaining within the EU will encourage more private healthcare providers into the NHS”, argues the anti-Brexit New European.
Speaking after Theresa May’s evasive Commons performance, an official spokesman later clarified that the prime minister had made clear that “the NHS is not for sale and it never will be” in February 2017.
The spokesman added: “Any trade deal ensures decisions about public services continue to be made by UK governments, not by our trade partners.
“The UK’s public health sector is protected by specific exceptions and reservations in all EU trade arrangements and, as we leave the EU, the UK will continue to ensure that rigorous protections for the NHS are included in all trade agreements it is party to.”
However, with the UK’s global standing and bargaining power greatly diminished outside the EU, and the Government desperate for a new trade deal with the US, access to the NHS may be a matter that comes up for discussion again.
Earlier this week, Donald Trump attacked the health service as “going broke and not working”.
Create an account with the same email registered to your subscription to unlock access.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
-
The new powers to stop stalking in the UK
The Explainer Updated guidance could help protect more victims, but public is losing trust in police and battered criminal justice system
By Harriet Marsden, The Week UK Published
-
'Criminal trail?'
Today's Newspapers A roundup of the headlines from the US front pages
By The Week Staff Published
-
Grindr 'shared user HIV status' with ad firms, lawsuit claims
Speed Read LGBTQ dating app accused of breaching UK data protection laws in case filed at London's High Court
By Rebecca Messina, The Week UK Published
-
Martha's Rule: patients given right to urgent second opinion
The Explainer Hospitals in England will launch new scheme that will allow access to a rapid treatment review
By Richard Windsor, The Week UK Published
-
The contaminated blood scandal
The Explainer Widely regarded as the worst treatment disaster in the history of the NHS, the public inquiry is due to publish its report in May
By The Week UK Published
-
Can Britain's dental crisis be fixed?
The Explainer New proposals include more money for dentists working in under-served areas
By Richard Windsor, The Week UK Published
-
Babylon Health: the failed AI wonder app that 'dazzled' politicians
The Explainer Demise of UK tech start-up is a cautionary tale for politicians seeking quick fixes to complicated problems
By The Week UK Last updated
-
Surgery faces ‘MeToo moment’ as female staff assaulted while operating
Two-thirds of women surgeons claim to have been sexually harassed and a third alleged assaults
By Chas Newkey-Burden Published
-
What does UK’s first womb transplant mean for future of fertility?
Today's Big Question Procedure could be offered more widely including to transgender people
By Chas Newkey-Burden Published
-
The NHS plan for virtual wards to beat winter crisis
feature Patients with respiratory infections to be given wearable devices that allow doctors to monitor them at home
By The Week Staff Published
-
The decline of the tampon
feature The environmental impact of the product ‘doesn’t fit well with Gen Z’
By Chas Newkey-Burden Published